menu
    • menu
    [{"orgOrder":0,"company":"Kedrion","sponsor":"Columbia University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Kedrion \/ Columbia University","highestDevelopmentStatusID":"4","companyTruncated":"Kedrion \/ Columbia University"},{"orgOrder":0,"company":"Kedrion","sponsor":"Kamada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Kedrion \/ Kedrion","highestDevelopmentStatusID":"7","companyTruncated":"Kedrion \/ Kedrion"},{"orgOrder":0,"company":"Kedrion","sponsor":"Kamada","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Kedrion \/ Kedrion","highestDevelopmentStatusID":"15","companyTruncated":"Kedrion \/ Kedrion"},{"orgOrder":0,"company":"Kedrion","sponsor":"Kamada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Kedrion \/ Kamada","highestDevelopmentStatusID":"15","companyTruncated":"Kedrion \/ Kamada"},{"orgOrder":0,"company":"Kedrion","sponsor":"Kamada","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Kedrion \/ Kedrion","highestDevelopmentStatusID":"11","companyTruncated":"Kedrion \/ Kedrion"},{"orgOrder":0,"company":"Kedrion","sponsor":"Kedrion","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"Plasminogen","moa":"||Plasminogen","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Lyophilized Powder","sponsorNew":"Kedrion \/ Kedrion","highestDevelopmentStatusID":"15","companyTruncated":"Kedrion \/ Kedrion"},{"orgOrder":0,"company":"Kedrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kedrion \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kedrion \/ Inapplicable"},{"orgOrder":0,"company":"Kedrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kedrion \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kedrion \/ Inapplicable"},{"orgOrder":0,"company":"Kedrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-protein Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Immunoglobulins","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Kedrion \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kedrion \/ Inapplicable"},{"orgOrder":0,"company":"Kedrion","sponsor":"Liminal BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Protein","year":"2021","type":"Divestment","leadProduct":"Plasminogen","moa":"||Plasminogen","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kedrion \/ Kedrion","highestDevelopmentStatusID":"10","companyTruncated":"Kedrion \/ Kedrion"},{"orgOrder":0,"company":"Kedrion","sponsor":"Liminal BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Protein","year":"2021","type":"Divestment","leadProduct":"Plasminogen","moa":"||Plasminogen","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Lyophilized Powder for Injection","sponsorNew":"Kedrion \/ Kedrion","highestDevelopmentStatusID":"15","companyTruncated":"Kedrion \/ Kedrion"},{"orgOrder":0,"company":"Kedrion","sponsor":"Prometic LifeSciences Inc","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"Plasminogen","moa":"||Plasminogen","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Lyophilized Powder for Injection","sponsorNew":"Kedrion \/ Kedrion","highestDevelopmentStatusID":"15","companyTruncated":"Kedrion \/ Kedrion"},{"orgOrder":0,"company":"Kedrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Human Immunoglobulin","moa":"||Fc receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kedrion \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kedrion \/ Inapplicable"},{"orgOrder":0,"company":"Kedrion","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Coagulation Factor X","moa":"||Coagulation factor X","graph1":"Hematology","graph2":"Phase III","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kedrion \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"10","companyTruncated":"Kedrion \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Kedrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Plasminogen","moa":"||Fibrinogen","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kedrion \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Kedrion \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Kedrion

    Menu

    Kedrion

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kedrion

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Kedrion

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Coagulation Factor X,Inapplicable

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Sponsor : Worldwide Clinical Trials

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis

                            Details : Undisclosed

                            Product Name : Coagadex

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 08, 2025

                            Lead Product(s) : Coagulation Factor X,Inapplicable

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Sponsor : Worldwide Clinical Trials

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kedrion

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Kedrion

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Immunoglobulin,Inapplicable

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammator...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            December 30, 2024

                            Lead Product(s) : Human Immunoglobulin,Inapplicable

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kedrion

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Kedrion

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rabies Immune Globulin (Human),Inapplicable

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Recipient : Kamada

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Kamada Announces Kedrion Exercised its Option for Two-Year Extension of KEDRAB® Distribution Agreement in the...

                            Details : The agreement aims for the distribution of Kedrab (Rabies Immune Globulin [Human]), which is indicated for passive, transient post-exposure prophylaxis of rabies infection to persons of all ages when given immediately after contact with a rabid, in the U...

                            Product Name : Kedrab

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            December 07, 2023

                            Lead Product(s) : Rabies Immune Globulin (Human),Inapplicable

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Recipient : Kamada

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kedrion

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Kedrion

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rabies Immune Globulin (Human),Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Kamada

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Kedrion Announces an Eight-Year Extension of the Distribution Agreement with Kamada in the US for Kedrab®

                            Details : The commercial agreement includes potential expansion of Kedrion's distribution of Kedrab, a Human Rabies Immune Globulin, in additional territories beyond the US. In addition, the two companies will collaborate to expand distribution of Kedrion products...

                            Product Name : Kedrab

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            July 12, 2023

                            Lead Product(s) : Rabies Immune Globulin (Human),Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Kamada

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Kedrion

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Kedrion

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Plasminogen,Inapplicable

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Approved FDF

                            Recipient : Prometic LifeSciences Inc

                            Deal Size : $17.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Kedrion Biopharma Grows in North America As it Completes Acquisition of Prometic

                            Details : With the acquisition of Prometic, Kedrion has finalized a series of transactions with the announcement that it was acquiring the plasma purification plant at Laval in Québec, and the license to distribute the new product called Ryplazim in the United St...

                            Product Name : Ryplazim

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            October 18, 2021

                            Lead Product(s) : Plasminogen,Inapplicable

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Approved FDF

                            Recipient : Prometic LifeSciences Inc

                            Deal Size : $17.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Kedrion

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Kedrion

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Kedrion IVIG,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First Patient Treated in KIDCARES10, Kedrion Biopharma Pediatric Primary Immunodeficiency Study

                            Details : The primary efficacy objective of KIDCARES10 is to assess the efficacy of KIg10 administered to patients with PI to demonstrate that the rate of acute serious bacterial infections is less than 1.0 to provide substantial evidence of efficacy from day 1 to...

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            July 13, 2021

                            Lead Product(s) : Kedrion IVIG,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Kedrion

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Kedrion

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Intravenous Immune Globulin,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES1...

                            Details : Undisclosed

                            Product Name : Kedrion IVIG

                            Product Type : Antibody-protein Conjugate

                            Upfront Cash : Inapplicable

                            June 30, 2021

                            Lead Product(s) : Intravenous Immune Globulin,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Kedrion

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Kedrion

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Plasminogen,Inapplicable

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Approved FDF

                            Recipient : Prometic Biotherapeutic

                            Deal Size : $17.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Liminal BioSciences Announces Signature of a Share Purchase Agreement for sale of Remaining Plasma-derived Bus...

                            Details : This acquisition would include the Ryplazim® (plasminogen, human-tvmh) (“Ryplazim®”) business operated through its subsidiaries, Prometic Bioproduction Inc., the Company’s plasma-derived therapeutics manufacturing facility (“PBP”), and Promet...

                            Product Name : Ryplazim

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            June 23, 2021

                            Lead Product(s) : Plasminogen,Inapplicable

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Approved FDF

                            Recipient : Prometic Biotherapeutic

                            Deal Size : $17.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Kedrion

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Kedrion

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Plasminogen,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Recipient : Liminal BioSciences

                            Deal Size : $22.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Liminal BioSciences Announces Closing of Divestiture of Plasma Collection Centers and Enters into Option Agree...

                            Details : Kedrion will enter into an option agreement with Liminal BioSciences to acquire the remainder of the company’s plasma-derived business, as well as Plasminogen business operated through its subsidiaries including Prometic Biotherapeutics which holds the...

                            Product Name : Ryplazim

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            May 17, 2021

                            Lead Product(s) : Plasminogen,Inapplicable

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Recipient : Liminal BioSciences

                            Deal Size : $22.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Kedrion

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Kedrion

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Plasminogen,Inapplicable

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Approved FDF

                            Recipient : Liminal BioSciences

                            Deal Size : $17.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Kedrion enters into Agreement with Liminal BioSciences

                            Details : According to terms and conditions, the Option would grant Kedrion the right to acquire all of the shares of PBP and PBT and would entitle Liminal BioSciences to receive up to seventy percent of the net proceeds, if granted, associated with a potential FD...

                            Product Name : Ryplazim

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            May 17, 2021

                            Lead Product(s) : Plasminogen,Inapplicable

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Approved FDF

                            Recipient : Liminal BioSciences

                            Deal Size : $17.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth